This prospective randomized clinical trial was approved by the Miami Veterans Affairs Medical Center Institutional Review Board and was HIPAA compliant. The study was registered with ClinicaTrials.gov ...
A novel intravitreal axitinib hydrogel demonstrated durable disease control in patients with treatment-naive neovascular age-related macular degeneration (AMD), with superior maintenance of visual ...
Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...
A new study suggests that eye drops developed by Columbia University researchers could be a more effective–and comfortable–therapy for a common eye disease currently treated with injections into the ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause irreversible ...
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results